ELEV Insider Transactions
| Transaction Date (SEC Report) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
|---|---|---|---|---|---|---|---|---|
| 2024-03-16 | Ferra Joseph J Jr | director, officer: CHIEF EXECUTIVE OFFICER | 90,453 | M-Exempt | A | 12,562 | 0.00 | 0.00 |
| 2024-03-16 | Ferra Joseph J Jr | director, officer: CHIEF EXECUTIVE OFFICER | 85,680 | F-InKind | D | 4,773 | 4.39 | 20,953.00 |
| 2024-03-16 | Ferra Joseph J Jr | director, officer: CHIEF EXECUTIVE OFFICER | 62,809 | M-Exempt | D | 12,562 | 0.00 | 0.00 |
| 2024-02-29 | Sandler Alan B. | director | 55,000 | A-Award | A | 55,000 | 4.41 | 242,550.00 |
| 2024-02-29 | Cherrington Julie M | director | 55,000 | A-Award | A | 55,000 | 4.41 | 242,550.00 |
| 2024-02-29 | Sandler Alan B. | 0 | 0 | 0.00 | 0.00 | |||
| 2024-02-29 | Cherrington Julie M | 0 | 0 | 0.00 | 0.00 | |||
| 2024-02-15 | Jansen Valerie Malyvanh | officer: CHIEF MEDICAL OFFICER | 225,000 | A-Award | A | 225,000 | 2.77 | 623,250.00 |
| 2024-02-15 | Jansen Valerie Malyvanh | officer: CHIEF MEDICAL OFFICER | 70,000 | A-Award | A | 70,000 | 0.00 | 0.00 |
| 2024-02-15 | Furlong Tammy | officer: CHIEF FINANCIAL OFFICER | 225,000 | A-Award | A | 225,000 | 2.77 | 623,250.00 |
| 2024-02-15 | Furlong Tammy | officer: CHIEF FINANCIAL OFFICER | 37,500 | A-Award | A | 37,500 | 0.00 | 0.00 |
| 2024-02-15 | Furlong Tammy | officer: CHIEF FINANCIAL OFFICER | 3,600 | M-Exempt | D | 1,200 | 0.00 | 0.00 |
| 2024-02-15 | Furlong Tammy | officer: CHIEF FINANCIAL OFFICER | 1,200 | M-Exempt | A | 1,200 | 0.00 | 0.00 |
| 2024-02-15 | Furlong Tammy | officer: CHIEF FINANCIAL OFFICER | 797 | F-InKind | D | 403 | 2.77 | 1,116.00 |
| 2024-02-15 | Dornan David | officer: CHIEF SCIENTIFIC OFFICER | 225,000 | A-Award | A | 225,000 | 2.77 | 623,250.00 |
| 2024-02-15 | Dornan David | officer: CHIEF SCIENTIFIC OFFICER | 37,500 | A-Award | A | 37,500 | 0.00 | 0.00 |
| 2024-02-15 | Ferra Joseph J Jr | director, officer: CHIEF EXECUTIVE OFFICER | 600,000 | A-Award | A | 600,000 | 2.77 | 1,662,000.00 |
| 2024-02-15 | Ferra Joseph J Jr | director, officer: CHIEF EXECUTIVE OFFICER | 100,000 | A-Award | A | 100,000 | 0.00 | 0.00 |
| 2024-01-18 | Mootz Darcy | director | 55,000 | A-Award | A | 55,000 | 2.74 | 150,700.00 |
| 2024-01-18 | Mootz Darcy | 0 | 0 | 0.00 | 0.00 | |||
| 2023-12-16 | Ferra Joseph J Jr | director, officer: CHIEF EXECUTIVE OFFICER | 82,664 | M-Exempt | A | 12,563 | 0.00 | 0.00 |
| 2023-12-16 | Ferra Joseph J Jr | director, officer: CHIEF EXECUTIVE OFFICER | 77,891 | F-InKind | D | 4,773 | 0.51 | 2,434.00 |
| 2023-12-16 | Ferra Joseph J Jr | director, officer: CHIEF EXECUTIVE OFFICER | 75,371 | M-Exempt | D | 12,563 | 0.00 | 0.00 |
| 2023-09-16 | Ferra Joseph J Jr | director, officer: CHIEF EXECUTIVE OFFICER | 87,934 | M-Exempt | D | 12,562 | 0.00 | 0.00 |
| 2023-09-16 | Ferra Joseph J Jr | director, officer: CHIEF EXECUTIVE OFFICER | 74,874 | M-Exempt | A | 12,562 | 0.00 | 0.00 |
| 2023-09-16 | Ferra Joseph J Jr | director, officer: CHIEF EXECUTIVE OFFICER | 70,101 | F-InKind | D | 4,773 | 0.73 | 3,475.00 |
| 2023-09-01 | CLACKSON TIMOTHY P | director | 0 | G-Gift | D | 15,777 | 0.00 | 0.00 |
| 2023-07-12 | Furlong Tammy | officer: CHIEF FINANCIAL OFFICER | 53,433 | A-Award | A | 53,433 | 1.51 | 80,684.00 |
| 2023-07-12 | Furlong Tammy | officer: CHIEF FINANCIAL OFFICER | 0 | D | 28,800 | 0.98 | 28,224.00 | |
| 2023-07-12 | Furlong Tammy | officer: CHIEF FINANCIAL OFFICER | 0 | D | 4,800 | 0.00 | 0.00 | |
| 2023-07-12 | Furlong Tammy | officer: CHIEF FINANCIAL OFFICER | 0 | D | 79,327 | 3.09 | 245,120.00 | |
| 2023-07-12 | Furlong Tammy | officer: CHIEF FINANCIAL OFFICER | 0 | D | 35,000 | 3.31 | 115,850.00 | |
| 2023-07-12 | Furlong Tammy | officer: CHIEF FINANCIAL OFFICER | 0 | D | 52,500 | 0.75 | 39,375.00 | |
| 2023-07-12 | Ferra Joseph J Jr | officer: CHIEF EXECUTIVE OFFICER | 35,000 | A-Award | A | 35,000 | 1.51 | 52,850.00 |
| 2023-06-16 | Walsh Colin | director | 31,238 | A-Award | A | 31,238 | 1.47 | 45,920.00 |
| 2023-06-16 | Hu Lori | director | 31,238 | A-Award | A | 31,238 | 1.47 | 45,920.00 |
| 2023-06-16 | CLACKSON TIMOTHY P | director | 31,238 | A-Award | A | 31,238 | 1.47 | 45,920.00 |
| 2023-06-16 | Carruthers R Michael | director | 31,238 | A-Award | A | 31,238 | 1.47 | 45,920.00 |
| 2023-06-16 | Aisling Capital IV, LP | 10 percent owner | 31,238 | A-Award | A | 31,238 | 1.47 | 45,920.00 |
| 2023-06-16 | Ferra Joseph J Jr | officer: INTERIM CEO & CFO | 100,496 | M-Exempt | D | 12,563 | 0.00 | 0.00 |
| 2023-06-16 | Ferra Joseph J Jr | officer: INTERIM CEO & CFO | 67,085 | M-Exempt | A | 12,563 | 0.00 | 0.00 |
| 2023-06-16 | Ferra Joseph J Jr | officer: INTERIM CEO & CFO | 62,312 | F-InKind | D | 4,773 | 1.47 | 7,016.00 |
| 2023-03-16 | Ferra Joseph J Jr | officer: INTERIM CEO & CFO | 113,059 | M-Exempt | D | 12,563 | 0.00 | 0.00 |
| 2023-03-16 | Ferra Joseph J Jr | officer: INTERIM CEO & CFO | 59,295 | M-Exempt | A | 12,563 | 0.00 | 0.00 |
| 2023-03-16 | Ferra Joseph J Jr | officer: INTERIM CEO & CFO | 54,522 | F-InKind | D | 4,773 | 2.35 | 11,217.00 |
| 2023-02-15 | Jansen Valerie Malyvanh | officer: CHIEF MEDICAL OFFICER | 130,000 | A-Award | A | 130,000 | 0.98 | 127,400.00 |
| 2023-02-15 | Dornan David | officer: CHIEF SCIENTIFIC OFFICER | 130,000 | A-Award | A | 130,000 | 0.98 | 127,400.00 |
| 2023-02-15 | Ferra Joseph J Jr | officer: INTERIM CEO & CFO | 270,000 | A-Award | A | 270,000 | 0.98 | 264,600.00 |
| 2023-01-06 | Jansen Valerie Malyvanh | director: CHIEF MEDICAL OFFICER | 130,000 | A-Award | A | 130,000 | 0.00 | 0.00 |
| 2023-01-06 | Dornan David | director: CHIEF SCIENTIFIC OFFICER | 130,000 | A-Award | A | 130,000 | 0.00 | 0.00 |
| 2023-01-06 | Ferra Joseph J Jr | director: INTERIM CEO & CFO | 240,000 | A-Award | A | 240,000 | 0.00 | 0.00 |
| 2023-01-06 | Ferra Joseph J Jr | director: INTERIM CEO & CFO | 30,000 | A-Award | A | 30,000 | 0.00 | 0.00 |
| 2022-06-16 | Ferra Joseph J Jr | director: CHIEF FINANCIAL OFFICER | 150,746 | M-Exempt | D | 50,249 | 0.00 | 0.00 |
| 2022-09-16 | Ferra Joseph J Jr | director: CHIEF FINANCIAL OFFICER | 138,184 | M-Exempt | D | 12,562 | 0.00 | 0.00 |
| 2022-12-16 | Ferra Joseph J Jr | director: CHIEF FINANCIAL OFFICER | 125,622 | M-Exempt | D | 12,562 | 0.00 | 0.00 |
| 2022-12-16 | Ferra Joseph J Jr | director: CHIEF FINANCIAL OFFICER | 51,505 | M-Exempt | A | 12,562 | 0.00 | 0.00 |
| 2022-06-16 | Ferra Joseph J Jr | director: CHIEF FINANCIAL OFFICER | 50,249 | M-Exempt | A | 50,249 | 0.00 | 0.00 |
| 2022-12-16 | Ferra Joseph J Jr | director: CHIEF FINANCIAL OFFICER | 46,732 | F-InKind | D | 4,773 | 0.95 | 4,534.00 |
| 2022-09-16 | Ferra Joseph J Jr | director: CHIEF FINANCIAL OFFICER | 43,716 | M-Exempt | A | 12,562 | 0.00 | 0.00 |
| 2022-09-16 | Ferra Joseph J Jr | director: CHIEF FINANCIAL OFFICER | 38,943 | F-InKind | D | 4,773 | 1.25 | 5,966.00 |
| 2022-06-16 | Ferra Joseph J Jr | director: CHIEF FINANCIAL OFFICER | 31,154 | F-InKind | D | 19,095 | 1.26 | 24,060.00 |
| 2022-06-17 | Walsh Colin | director: | 15,619 | A-Award | A | 15,619 | 0.00 | 0.00 |
| 2022-06-17 | Hu Lori | director: | 15,619 | A-Award | A | 15,619 | 0.00 | 0.00 |
| 2022-06-17 | SCHIFF ANDREW N | director: | 15,619 | A-Award | A | 15,619 | 0.00 | 0.00 |
| 2022-06-17 | Aisling Capital IV, LP | 10 percent owner | 15,619 | A-Award | A | 15,619 | 1.31 | 20,461.00 |
| 2022-06-17 | CLACKSON TIMOTHY P | director: | 15,777 | G-Gift | D | 31,553 | 0.00 | 0.00 |
| 2022-06-17 | CLACKSON TIMOTHY P | director: | 15,619 | A-Award | A | 15,619 | 0.00 | 0.00 |
| 2022-06-17 | CLACKSON TIMOTHY P | director | 15,619 | A-Award | A | 15,619 | 1.31 | 20,461.00 |
| 2022-06-17 | Carruthers R Michael | director: | 15,619 | A-Award | A | 15,619 | 0.00 | 0.00 |
| 2022-05-25 | Royston Aaron | director: | 1,905,430 | S-Sale | D | 702,737 | 4.12 | 2,897,806.00 |
| 2022-05-25 | venBio Global Strategic Fund III, L.P. | 10 percent owner | 1,905,430 | S-Sale | D | 702,737 | 4.12 | 2,897,806.00 |
| 2022-03-14 | Dornan David | officer: Chief Scientific Officer | 230,000 | A-Award | A | 230,000 | 0.00 | 0.00 |
| 2022-03-14 | Dornan David | officer | 0 | 0 | 0.00 | 0.00 | ||
| 2022-02-14 | Jansen Valerie Malyvanh | officer: Chief Medical Officer | 60,000 | A-Award | A | 60,000 | 3.78 | 226,800.00 |
| 2022-02-14 | Leland Shawn | director, officer: President, CEO | 186,500 | A-Award | A | 186,500 | 3.78 | 704,970.00 |
| 2022-02-14 | Ferra Joseph J Jr | officer: Chief Financial Officer | 60,000 | A-Award | A | 60,000 | 3.78 | 226,800.00 |
| 2021-10-19 | Jansen Valerie Malyvanh | officer: Chief Medical Officer | 40,000 | A-Award | A | 40,000 | 7.58 | 303,200.00 |
| 2021-10-19 | Jansen Valerie Malyvanh | officer: Chief Medical Officer | 0 | D | 158,654 | 3.09 | 490,241.00 | |
| 2021-06-29 | Qiming U.S. Healthcare Fund II, L.P. | 10 percent owner | 2,370,142 | P-Purchase | A | 312,500 | 16.00 | 5,000,000.00 |
| 2021-06-29 | Qiming U.S. Healthcare Fund II, L.P. | 10 percent owner | 2,057,642 | C-Conversion | A | 401,065 | 0.00 | 0.00 |
| 2021-06-29 | Qiming U.S. Healthcare Fund II, L.P. | 10 percent owner | 1,656,577 | C-Conversion | A | 1,656,577 | 0.00 | 0.00 |
| 2021-06-29 | Qiming U.S. Healthcare Fund II, L.P. | 10 percent owner | 0 | C-Conversion | D | 1,694,730 | 0.00 | 0.00 |
| 2021-06-29 | Qiming U.S. Healthcare Fund II, L.P. | 10 percent owner | 0 | C-Conversion | D | 7,000,000 | 0.00 | 0.00 |
| 2021-06-29 | Aisling Capital IV, LP | 10 percent owner | 2,834,910 | P-Purchase | A | 187,500 | 16.00 | 3,000,000.00 |
| 2021-06-29 | Aisling Capital IV, LP | 10 percent owner | 2,647,410 | C-Conversion | A | 458,360 | 0.00 | 0.00 |
| 2021-06-29 | Aisling Capital IV, LP | 10 percent owner | 2,189,050 | C-Conversion | A | 1,893,232 | 0.00 | 0.00 |
| 2021-06-29 | Aisling Capital IV, LP | 10 percent owner | 0 | C-Conversion | D | 1,936,834 | 0.00 | 0.00 |
| 2021-06-29 | Aisling Capital IV, LP | 10 percent owner | 0 | C-Conversion | D | 8,000,000 | 0.00 | 0.00 |
| 2021-06-29 | venBio Global Strategic Fund III, L.P. | 10 percent owner | 2,608,167 | P-Purchase | A | 625,000 | 16.00 | 10,000,000.00 |
| 2021-06-29 | venBio Global Strategic Fund III, L.P. | 10 percent owner | 1,983,167 | C-Conversion | A | 1,983,167 | 0.00 | 0.00 |
| 2021-06-29 | venBio Global Strategic Fund III, L.P. | 10 percent owner | 0 | C-Conversion | D | 8,380,034 | 0.00 | 0.00 |
| 2021-06-29 | Cormorant Asset Management, LP | 2,233,168 | P-Purchase | A | 250,000 | 16.00 | 4,000,000.00 | |
| 2021-06-29 | Cormorant Asset Management, LP | 1,983,168 | C-Conversion | A | 1,983,168 | 0.00 | 0.00 | |
| 2021-06-29 | Cormorant Asset Management, LP | 0 | C-Conversion | D | 1,983,168 | 0.00 | 0.00 | |
| 2021-06-29 | Vertex Global HC Fund II Pte. Ltd. | 10 percent owner | 2,307,642 | P-Purchase | A | 250,000 | 16.00 | 4,000,000.00 |
| 2021-06-29 | Vertex Global HC Fund II Pte. Ltd. | 10 percent owner | 2,057,642 | C-Conversion | A | 401,065 | 0.00 | 0.00 |
| 2021-06-29 | Vertex Global HC Fund II Pte. Ltd. | 10 percent owner | 1,656,577 | C-Conversion | A | 1,656,577 | 0.00 | 0.00 |
| 2021-06-29 | Vertex Global HC Fund II Pte. Ltd. | 10 percent owner | 0 | C-Conversion | D | 7,000,000 | 0.00 | 0.00 |
| 2021-06-29 | Vertex Global HC Fund II Pte. Ltd. | 10 percent owner | 0 | C-Conversion | D | 1,694,730 | 0.00 | 0.00 |
| 2021-06-24 | Gaster Richard | director | 31,238 | A-Award | A | 31,238 | 16.00 | 499,808.00 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
